Sinovac’s COVID-19 Vaccine Over 50% Effective, Reports Newspaper Folha

RIO DE JANEIRO, BRAZIL – Sinovac Biotech’s vaccine against COVID-19 is over 50% effective in late-stage trials, newspaper Folha de S. Paulo reported on Wednesday, December 23rd, adding that the Chinese company had asked the Brazilian institute running tests to wait up to 15 days before publishing their full results.

The Butantan Institute, which is running the trial in Brazil, and the government of São Paulo, which oversees the institute, declined to comment, saying there would be more details in a news conference at 4 p.m. local time.

Related coverage: Indonesia Requests Clinical Trial Data from Brazil After Its Own Vaccine Trials Lag · Southern Brazil Faces Hardest Side of Pandemic · Brazilian Tourists Banned from Entering Argentina as of Friday · Butantan Institute Claims CoronaVac Is "Safest" Vaccine Tested in Brazil

More: Brazil news in English, every day from The Rio Times.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

Brazil runoff, Sunday, October 25: Brazil runoff date. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.